MX2009008756A - Compuesto macrociclico. - Google Patents

Compuesto macrociclico.

Info

Publication number
MX2009008756A
MX2009008756A MX2009008756A MX2009008756A MX2009008756A MX 2009008756 A MX2009008756 A MX 2009008756A MX 2009008756 A MX2009008756 A MX 2009008756A MX 2009008756 A MX2009008756 A MX 2009008756A MX 2009008756 A MX2009008756 A MX 2009008756A
Authority
MX
Mexico
Prior art keywords
compound
disclosed
macrocyclic compound
useful
inhibitory activity
Prior art date
Application number
MX2009008756A
Other languages
English (en)
Inventor
Nobuo Shimma
Masami Kohchi
Takuo Tsukuda
Ken-Ichi Kawasaki
Susumu Komiyama
Kiyoshi Hasegawa
Naomi Ono
Toshikazu Yamazaki
Hiroshi Koyano
Atsushi Suda
Tadakatsu Hayase
Kihito Hada
Ryoichi Saitoh
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2009008756A publication Critical patent/MX2009008756A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Abstract

Se describe una nueva clase de compuesto con actividad inhibidora de HSP90 y que es útil como agente antitumoral o similares. También se describe un compuesto que es útil como un intermediario sintético para el compuesto que tiene actividad inhibidora de HSP90. Específicamente, se describe un compuesto representado por la fórmula general (1) siguiente, o una sal de él aceptable farmacéuticamente. (En la fórmula, X, R1, R2, R3, R4, R5, R6, R7, L1, L2, y L3 son como se define en la descripción).
MX2009008756A 2007-03-01 2008-02-29 Compuesto macrociclico. MX2009008756A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007052072 2007-03-01
PCT/JP2008/053599 WO2008105526A1 (ja) 2007-03-01 2008-02-29 マクロ環状化合物

Publications (1)

Publication Number Publication Date
MX2009008756A true MX2009008756A (es) 2009-08-27

Family

ID=39721348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008756A MX2009008756A (es) 2007-03-01 2008-02-29 Compuesto macrociclico.

Country Status (18)

Country Link
US (1) US8362236B2 (es)
EP (1) EP2119718B1 (es)
JP (1) JP5235859B2 (es)
KR (1) KR20090125155A (es)
CN (1) CN101675059A (es)
AR (1) AR065583A1 (es)
AT (1) ATE553107T1 (es)
AU (1) AU2008220009A1 (es)
BR (1) BRPI0808524A2 (es)
CA (1) CA2679126A1 (es)
CL (1) CL2008000629A1 (es)
IL (1) IL200009A0 (es)
MX (1) MX2009008756A (es)
PE (1) PE20090110A1 (es)
RU (1) RU2009136343A (es)
TW (1) TW200904435A (es)
WO (1) WO2008105526A1 (es)
ZA (1) ZA200905116B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061185A1 (es) * 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
MX2009008756A (es) 2007-03-01 2009-08-27 Chugai Pharmaceutical Co Ltd Compuesto macrociclico.
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
MX350844B (es) 2012-03-06 2017-09-22 Pfizer Derivados macrocíclicos para el tratamiento de enfermedades proliferativas.
AU2013234499B2 (en) * 2012-03-17 2017-07-27 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
US9617282B2 (en) 2013-03-15 2017-04-11 Biogen Ma Inc. Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases
DK3053578T3 (da) 2013-09-30 2021-02-01 Taiho Pharmaceutical Co Ltd Kombinationscancerterapi ved hjælp af azabicycloforbindelse
EP3623378A4 (en) * 2017-05-12 2021-03-03 Chugai Seiyaku Kabushiki Kaisha METHOD OF MAKING A CYCLIC ORGANIC COMPOUND
CN115124550B (zh) * 2020-10-26 2024-04-02 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5170780A (ja) 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinabenzoguanidoruino seiho
JPS60208968A (ja) 1984-03-07 1985-10-21 イー・アイ・デユポン・デ・ニモアス・アンド・カンパニー 除草剤性フルオロエトキシピリミジン類及びトリアジン類
AU585761B2 (en) 1984-03-07 1989-06-22 E.I. Du Pont De Nemours And Company Herbicidal fluoroethoxy triazines
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US6177423B1 (en) 1996-11-01 2001-01-23 Warner-Lambert Company Isoquinolones
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
AU780527B2 (en) 2000-02-25 2005-03-24 F. Hoffmann-La Roche Ag Adenosine receptor modulators
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
CA2417495C (en) 2000-07-28 2013-04-30 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
JP2004512381A (ja) 2000-11-02 2004-04-22 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法
KR100850727B1 (ko) 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
WO2003037346A1 (en) 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
EP1321169A1 (en) 2001-12-18 2003-06-25 Biofrontera Pharmaceuticals AG Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
WO2003066005A2 (en) 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
US7419984B2 (en) 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
AU2004268820B2 (en) 2003-08-29 2011-07-21 Cancer Research Technology Ltd Pyrimidothiophene compounds
JP2005225787A (ja) * 2004-02-12 2005-08-25 Nippon Kayaku Co Ltd Ｈｓｐ９０阻害剤
GB0416168D0 (en) 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
EP2049497A2 (en) 2005-05-19 2009-04-22 Astex Therapeutics Limited Pyrimidine derivatives as hsp90 inhibitors
TWI506029B (zh) * 2005-11-16 2015-11-01 Cti Biopharma Corp 氧連接之嘧啶衍生物
AR061185A1 (es) * 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
MX2009008756A (es) 2007-03-01 2009-08-27 Chugai Pharmaceutical Co Ltd Compuesto macrociclico.
JP2009067729A (ja) 2007-09-14 2009-04-02 Kyowa Hakko Kirin Co Ltd Ｈｓｐ９０ファミリー蛋白質阻害剤
EP2252595B1 (en) 2008-02-01 2014-03-26 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors

Also Published As

Publication number Publication date
EP2119718B1 (en) 2012-04-11
BRPI0808524A2 (pt) 2014-11-11
CL2008000629A1 (es) 2008-08-29
PE20090110A1 (es) 2009-04-04
CN101675059A (zh) 2010-03-17
JP5235859B2 (ja) 2013-07-10
CA2679126A1 (en) 2008-09-04
EP2119718A4 (en) 2010-12-15
WO2008105526A1 (ja) 2008-09-04
EP2119718A1 (en) 2009-11-18
AR065583A1 (es) 2009-06-17
US20100056510A1 (en) 2010-03-04
IL200009A0 (en) 2010-04-15
ZA200905116B (en) 2010-07-28
ATE553107T1 (de) 2012-04-15
AU2008220009A1 (en) 2008-09-04
KR20090125155A (ko) 2009-12-03
TW200904435A (en) 2009-02-01
JPWO2008105526A1 (ja) 2010-06-03
RU2009136343A (ru) 2011-04-10
US8362236B2 (en) 2013-01-29

Similar Documents

Publication Publication Date Title
MX2009008756A (es) Compuesto macrociclico.
TW200642683A (en) Heterocyclic compound
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2008087933A1 (ja) ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
TW200612958A (en) Substituted imidazole derivatives
TW200728307A (en) Novel spirochromanone derivatives
TW200740758A (en) Benzoquinazoline derivatives
WO2009020140A1 (ja) アダマンチルウレア誘導体
WO2009016462A3 (en) Substituted bicyclolactam compounds
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
EP1889842A4 (en) HETEROCYCLIC CONNECTION
WO2008108386A1 (ja) 医薬組成物
WO2008120759A1 (ja) ウレア化合物およびその用途
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
WO2008079836A3 (en) Macrocyclic factor viia inhibitors useful as anticoagulants
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
MX2010001566A (es) Derivado de aminopirazolamida.
TW200745033A (en) Oxindole derivative as feeding control agent
TW200714593A (en) Agent for treatment of solid tumor
MY136824A (en) Substituted benzoxazinones and uses thereof
WO2007103762A3 (en) Compositions and methods of use of electron transport system inhibitors
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
TW200720265A (en) Agent for treatment of hematopoietic tumor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal